Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Active Biotech AB (ACTI.ST)
Lund, SN, SE
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.27% | -5.48% | -3.93% | +51.81% | -5.32% | +27.39% | -36.85% | -76.93% | -89.67% | -92.53% | -99.79% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+70.4% ★ Q1'26: +64.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +573.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+220.5% Q1'26: +114.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
16.28M
est: 109.75M (-85.2%)
|
19.04M
est: 16.38M (+16.3%)
|
20.25M
est: 391.66M (-94.8%)
|
20.05M
est: 562.00M (-96.4%)
|
8.43M
est: 765.00M (-98.9%)
|
6.73M
est: 7.00M (-3.9%)
|
—
est: 1.50M (-100.0%)
|
—
est: 28.00M (-100.0%)
|
21.50M
21.50M – 21.50M
-23.2% YoY
|
25.05M
25.05M – 25.05M
+16.5% YoY
|
| EBITDA |
-165.83M
est: 65.85M (-351.8%)
|
-45.76M
est: 9.83M (-565.6%)
|
-96.62M
est: 234.99M (-141.1%)
|
-29.46M
est: 337.20M (-108.7%)
|
-31.33M
est: 459.00M (-106.8%)
|
-30.84M
est: 4.20M (-834.2%)
|
-38.30M
|
-36.00M
|
—
— – —
|
—
— – —
|
| EBIT |
-177.87M
est: 65.85M (-370.1%)
|
-54.67M
est: 9.83M (-656.3%)
|
-102.76M
est: 234.99M (-143.7%)
|
-29.91M
est: 337.20M (-108.9%)
|
-32.20M
est: 459.00M (-107.0%)
|
-32.16M
est: 4.20M (-865.7%)
|
-39.90M
|
-37.60M
|
—
— – —
|
—
— – —
|
| Net Income |
-193.53M
est: -89.00M (-117.4%)
|
-59.58M
est: -1.61M (-3,609.0%)
|
-108.79M
est: 250.14M (-143.5%)
|
-36.88M
est: 352.32M (-110.5%)
|
-36.07M
est: 485.34M (-107.4%)
|
-32.12M
est: -22.91M (-40.2%)
|
-39.40M
est: -96.54M (+59.2%)
|
-37.30M
est: -21.38M (-74.5%)
|
-60.84M
-60.84M – -60.84M
-184.5% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
17.97M
est: 131.81M (-86.4%)
|
15.92M
est: 19.67M (-19.1%)
|
20.17M
est: 470.36M (-95.7%)
|
10.58M
est: 674.93M (-98.4%)
|
12.24M
est: 918.73M (-98.7%)
|
13.48M
est: 8.41M (+60.4%)
|
13.20M
|
10.80M
|
—
— – —
|
—
— – —
|
| EPS |
-1.29
est: -0.21 (-509.4%)
|
-0.40
est: 0.00 (-10,368.5%)
|
-0.72
est: 0.59 (-221.0%)
|
-0.22
est: 0.84 (-126.3%)
|
-0.18
est: 1.15 (-115.6%)
|
-0.19
est: -0.05 (-248.7%)
|
-0.09
est: -0.07 (-30.8%)
|
-0.03
est: -0.02 (-74.6%)
|
-0.05
-0.05 – -0.05
-184.5% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Helen Tuvesson | President & Chief Executive Officer | 4M | female |
| Erik Vahtola | Chief Medical Officer | — | — |
| Hans Kolam | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACTI.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
